Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbations. METHODS: This multicenter retrospectiv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Martinez Chanza, Nieves, Xie, Wanling, Issa, Majd, Dzimitrowicz, Hannah, Tripathi, Abhishek, Beuselinck, Benoit, Lam, Elaine, Zakharia, Yousef, Mckay, Rana, Shah, Sumit, Mortazavi, Amir, R. Harrison, Michael, Sideris, Spyridon, Kaymakcalan, Marina D, Abou Alaiwi, Sarah, Nassar, Amin H, Nuzzo, Pier Vitale, Hamid, Anis, K Choueiri, Toni, C Harshman, Lauren
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Clinical/Translational Cancer Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://ncbi.nlm.nih.gov/pubmed/32217762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000538
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge